Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Regeneron, sanofi-aventis deal

REGN and SAN partnered to discover, develop and commercialize human therapeutic antibodies using REGN's VelociSuite technologies, including its VelocImmune MAb technology. SAN also will pay $312

Read the full 261 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE